

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

000 2/20
515363
Licensee

In accordance with the letter dated

June 7, 2011,

3. License number 24-11858-01 is amended in its entirety to read as follows:

4. Expiration date May 31, 2015

5. Docket No. 030-02368

Reference No.

1. SSM St. Clare Health Center

2. 1015 Bowles Avenue
Fenton, MO 63026

6. Byproduct, source, and/or special nuclear material

7. Chemical and/or physical form

8. Maximum amount that licensee may possess at any one time under this license

A. Any byproduct material permitted by 10 CFR 35.100

A. Any

A. As needed

B. Any byproduct material permitted by 10 CFR 35.200

B. Any

B. As needed

C. Any byproduct material permitted by 10 CFR 35.300

C. Any

C. As needed (not to exceed 150 millicuries of iodine-131)

D. Any byproduct material permitted by 10 CFR 35.400

D. Sealed sources (Best Medical Int'l. 81-01, 2301 to 2316, 2331, 2335; North American Scientific Med 3633, 363; Theragenics Corp. 200, Mills Biopharm. 103 SL and I-125 SL (Prostaseed); Int'l. Brachytherapy SA 1031L and 1251L, Syncor BT-125-1, Medi-Physics 6733 (Echoseed) and 6711 (Oncoseed), IsoAid IAI-125A (Advantage), and Implant Sciences Corp. 3500 (I-plant); Bard Brachtherapy Inc. STM 1251; IsoAid LLC IAPd-103A).

D. 4 curies

9. Authorized use:

A. Any uptake, dilution and excretion study permitted by 10 CFR 35.100.

B. Any imaging and localization study permitted by 10 CFR 35.200.

C. Any diagnostic study or therapy procedure permitted by 10 CFR 35.300.

D. Any manual brachytherapy procedure permitted by 10 CFR 35.400.

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**License Number
24-11858-01
Docket or Reference Number
030-02368

Amendment No. 50

CONDITIONS

10. Licensed material listed in above. may be used and stored at 1015 Bowles Avenue, Fenton, Missouri.
11. The Radiation Safety Officer for this license is Andre Strzembosz, M.D.
12. Licensed material is only authorized for use by, or under the supervision of:
- A. Individuals permitted to work as an authorized user, authorized nuclear pharmacist, and/or authorized medical physicist in accordance with 10 CFR 35.13 and 35.14.
- B. The following individuals are authorized users for medical use as indicated:

Authorized UsersMaterial and Use

Larry Paskar, M.D.

10 CFR 35.100 and 35.200.

Edwin C. Ernst, III, M.D.

10 CFR 35.100, 35.200 and 35.300.

Ronald Palmer, M.D.

10 CFR 35.100, 35.200 and 35.300.

Andre Strzembosz, M.D.

10 CFR 35.100, 35.200 and 35.300.

James G. Stewart, M.D.

10 CFR 35.100 and 35.200.

Karen J. Baranski, M.D.

10 CFR 35.100 and 35.200.

Thomas P. Bocchini, M.D.

10 CFR 35.100 and 35.200.

Robert J. Gresick, M.D.

10 CFR 35.100 and 35.200.

Michael G. Beat, M.D.

10 CFR 35.300 and 35.400.

Megan Maine Gau, M.D.

10 CFR 35.100 and 35.200.

Vincent Q. Joe, M.D.

10 CFR 35.400.

Robert Swanson, M.D.**10 CFR 35.300 and 35.400 (limited to the use of
palladium-103 and iodine-125).**

13. The licensee is authorized to transport licensed material only in accordance with the provisions of 10 CFR Part 71, "Packaging and Transportation of Radioactive Material."
14. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material to quantities below the minimum limit specified in 10 CFR 30.35(d) for establishing decommissioning financial assurance.
15. Sealed sources containing licensed material shall not be opened or sources removed from source holders by the licensee.

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License Number

24-11858-01

Docket or Reference Number

030-02368


Amendment No. 50

16. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.
- A. Letters dated December 17, 2004 (with attached application), December 2, 2005, March 7, 2007, January 22, 2009, June 12, 2009, September 3, 2009; and
- B. Facsimile dated August 28, 2009.

FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Date JUL 29 2011

By



Toye L. Simmons
Materials Licensing Branch
Region III